Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme

Published On 2025-11-29 17:07 GMT | Update On 2025-11-29 17:07 GMT

New Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval for updating the Prescribing Information of Xenpozyme (Olipudase alfa Powder for concentrate for solution for infusion 20 mg vial), manufactured by Sanofi Healthcare India.

This came after the firm presented the proposal of an update in Prescribing Information for Xenpozyme (Olipudasealfa Powder for concentrate for solution for infusion 20 mg vial) in line with Company Core Data Sheet (CCDS) version 04 dated 27th Oct 2022 and version 07 dated 27th June 2024.

Olipudase alfa is a recombinant human acid sphingomyelinase used to treat Acid Sphingomyelinase Deficiency (ASMD) in children and adults.

It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease. ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin. Olipudase alfa works to hydrolyze sphingomyelin accumulated in body tissues, such as the lungs, liver, spleen, kidneys, and bone marrow.

Also Read: CDSCO Panel Recommends Updating Prescribing Information for Sanofi's Vaccine

At the recent SEC meeting held on 09 October 2025, the expert panel reviewed the firm's submission in detail.

After detailed deliberation, the committee recommended the proposal of Update of Prescribing Information for Xenpozyme (Olipudasealfa Powder for concentrate for solution for infusion 20 mg vial) in line with Company Core Data Sheet (CCDS) version 04 dated 27th Oct 2022 and version 07 dated 27th June 2024.

Also Read: Sanofi gets Japenese nod for Xenpozyme to treat acid sphingomyelinase deficiency

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme

Similar News

DCC Flags State-Level Gaps, Calls for Nationwide Uniform Enforcement of Drug Quality Standards

CDSCO Panel Clears Bristol Myers' Yervoy for Two New Cancer Indications

CDSCO Panel Directs Mankind Pharma to Conduct Phase I Trial of Sintilimab Before Phase III Launch

State Drug Alert: 148 Medicine Samples Fail CDSCO Quality Tests in October

Intas Pharma Gets CDSCO Panel Nod to Conduct Phase I Trial of Pertuzumab, Trastuzumab Solution for Injection

CDSCO Flags 5 Batches of Widely Used Drugs Including Azithral-500, Telma-AM as Potentially Spurious

Johnson and Johnson Told to Justify Phase III Icotrokinra Trial Design Over Sample Size, Patient Exposure